Acurx Pharmaceuticals, Inc.
ACXP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.09
KIRA · Stoqly’s AI analyst, in plain words
- Acurx Pharmaceuticals, Inc. lost $8.0M in fiscal 2025.
Market cap
$4.6M
P/E
—
Revenue
—
Net income
−$8.0M
Free cash flow
—
Operating margin
—
Acurx Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Acurx Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Acurx Pharmaceuticals, Inc.
- CIK
- 0001736243
Acurx Pharmaceuticals, Inc. · ACXP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.7M | −$12.1M | −$14.6M | −$14.1M | −$8.0M |
| Diluted EPS | −$1.49 | −$1.12 | −$1.15 | −$17.45 | −$5.32 |
| Cash | |||||
| Cash from operations | −$5.0M | −$7.5M | −$9.8M | −$10.4M | −$6.8M |
| Share count change | 37.9% | 26.7% | 17.2% | −93.6% | 85.4% |
| Debt and strength | |||||
| Cash and short-term investments | $13.0M | $9.1M | $7.5M | $3.7M | $7.6M |
| Shareholders' equity | $12.4M | $7.3M | $4.7M | $0.6M | $5.3M |
| Current ratio | 15.7x | 4.5x | 2.5x | 1.2x | — |
| Returns and quality | |||||
| Return on equity | −168.7% | −122.6% | −243.3% | −534.0% | −270.8% |
| Return on tangible equity | −102.7% | −165.3% | −312.4% | −2,292.8% | −151.2% |
| Altman Z'' | — | — | — | −80.2 | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Acurx Pharmaceuticals, Inc. · ACXP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.09 a share, the company is worth $4.6M.
Source: SEC EDGAR XBRL filings (CIK 0001736243). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.